Abrahams Katherine A, Besra Gurdyal S
Institute of Microbiology and Infection,School of Biosciences,University of Birmingham,Edgbaston,Birmingham B15 2TT,UK.
Parasitology. 2018 Feb;145(2):116-133. doi: 10.1017/S0031182016002377. Epub 2016 Dec 15.
Mycobacterium tuberculosis (Mtb), the etiological agent of tuberculosis (TB), is recognized as a global health emergency as promoted by the World Health Organization. Over 1 million deaths per year, along with the emergence of multi- and extensively-drug resistant strains of Mtb, have triggered intensive research into the pathogenicity and biochemistry of this microorganism, guiding the development of anti-TB chemotherapeutic agents. The essential mycobacterial cell wall, sharing some common features with all bacteria, represents an apparent 'Achilles heel' that has been targeted by TB chemotherapy since the advent of TB treatment. This complex structure composed of three distinct layers, peptidoglycan, arabinogalactan and mycolic acids, is vital in supporting cell growth, virulence and providing a barrier to antibiotics. The fundamental nature of cell wall synthesis and assembly has rendered the mycobacterial cell wall as the most widely exploited target of anti-TB drugs. This review provides an overview of the biosynthesis of the prominent cell wall components, highlighting the inhibitory mechanisms of existing clinical drugs and illustrating the potential of other unexploited enzymes as future drug targets.
结核分枝杆菌(Mtb)是结核病(TB)的病原体,正如世界卫生组织所倡导的那样,它被视为全球卫生紧急情况。每年有超过100万人死亡,以及Mtb多重耐药和广泛耐药菌株的出现,引发了对这种微生物致病性和生物化学的深入研究,推动了抗结核化疗药物的研发。基本的分枝杆菌细胞壁与所有细菌有一些共同特征,自结核病治疗出现以来,它一直是结核病化疗的明显“阿喀琉斯之踵”。这种由肽聚糖、阿拉伯半乳聚糖和分枝菌酸三个不同层组成的复杂结构,对于支持细胞生长、毒力以及对抗生素形成屏障至关重要。细胞壁合成和组装的基本性质使分枝杆菌细胞壁成为抗结核药物应用最为广泛的靶点。本综述概述了突出的细胞壁成分的生物合成,强调了现有临床药物的抑制机制,并阐述了其他未开发酶作为未来药物靶点的潜力。